Idiopathic myelofibrosis; Myeloid metaplasia; Agnogenic myeloid metaplasia; Primary myelofibrosis; Secondary myelofibrosis
Prevention
There is no known prevention.
References
Tefferi A. Myeloproliferative disorders: essential thrombocythemia and primary myelofibrosis. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier;2007:chap 177.
Previous Section
Review Date: 06/02/2010
Reviewed By: David C. Dugdale, III, MD, Professor of Medicine, Division of
General Medicine, Department of Medicine, University of Washington
School of Medicine; and Yi-Bin Chen, MD, Leukemia/Bone Marrow
Transplant Program, Massachusetts General Hospital. Also reviewed
by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org)
